RT
Rubik Therapeutics develops targeted cancer therapies, including CAR-T, radioligand, and ADC treatments, by leveraging highly selective tumor-specific targets identified through genomic dysregulation. The company utilizes its proprietary Oncolinkage platform to optimize these targets for best-in-class selectivity across multiple therapeutic modalities. This approach yields partner-ready programs focused on advancing precision oncology treatments for significant patient populations.
Updated 20 months ago
Funding
Funding not disclosed
IA
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Rubik Therapeutics develops targeted cancer therapies, including CAR-T, radioligand, and ADC treatments, by leveraging highly selective tumor-specific targets identified through genomic dysregulation. The company utilizes its proprietary Oncolinkage platform to optimize these targets for best-in-class selectivity across multiple therapeutic modalities. This approach yields partner-ready programs focused on advancing precision oncology treatments for significant patient populations.